A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer- GeparPiPPa
- Promotore
- GBG Forschungs GmbH
- Acronimo
- GBG 105
- Struttura
- Oncologia
- Sperimentatore principale
- Vincenti Maura
- Stato arruolamento
- In attesa di arruolamento